Updated July 2026. No therapeutic HIV vaccine has demonstrated durable virological control off antiretroviral therapy (ART). Recent notable candidates: HIV-v (SQZ Biotech, PBMC-based) — Phase 1 completed; Vacc-4x + revimmune (Bionor Immuno) — Phase 2 showed modest viral load reduction; iHIVARNA (mRNA-based) — Phase 2 disappointing efficacy. Broadly neutralizing antibody combinations (3BNC117, 10-1074) remain a parallel path to functional cure. The "shock and kill" strategy pairing latency-reversing agents with therapeutic vaccines continues in academic Phase 1/2 studies. Field consensus remains that a functional cure is likely 10+ years away.
Comprehensive tracking of HIV therapeutic vaccine development for people living with HIV, targeting functional cure (ART-free viral remission). HIV affects 39 million globally (1.2 million US), controlled by antiretroviral therapy (ART) but NOT cured - lifelong daily medication required. HIV establishes latent reservoirs in CD4+ T cells (primarily resting memory T cells) that persist despite ART, viral DNA integrated into host genome dormant but reactivation-competent. Stop ART → viral rebound within 2-4 weeks from reservoir reactivation. Therapeutic vaccines aim to: (1) "Kick" - reverse latency forcing virus expression, (2) "Kill" - boost HIV-specific immunity eliminating reactivated infected cells, achieving functional cure (virus remains but immune control prevents replication without ART). Leading strategies: Therapeutic vaccines + latency reversal agents (LRAs), broadly neutralizing antibodies (bnAbs), mosaic vaccines, dendritic cell vaccines. Only 2 proven cures: Timothy Ray Brown (Berlin Patient), Adam Castillejo (London Patient) - both via stem cell transplants from CCR5Δ32 donors (not scalable). Goal: Scalable functional cure 70%+ achieving ART-free remission years. Complementary to antiretroviral therapy and HIV management.
HIV affects 39 million people globally (1.2 million US, 1.7 million children worldwide), 38 million on antiretroviral therapy (ART). Modern ART revolutionized HIV from death sentence to chronic manageable disease - life expectancy near-normal (70+ years), viral suppression achieves "undetectable = untransmittable" (U=U, cannot transmit sexually). However ART does NOT cure: (1) Lifelong daily medication required (1-3 pills/day, cost $20,000-40,000/year US, $100-300/year generic developing countries with subsidies), (2) Side effects - GI upset, fatigue, bone loss, cardiovascular risk, neuropsychiatric effects, kidney/liver toxicity (varies by regimen), (3) Adherence challenges - 95%+ adherence needed, missed doses → resistance, stigma/disclosure issues, (4) Drug-drug interactions complicating other medical care, (5) Long-term toxicities uncertain (decades of ART). Latent HIV reservoir problem: Virus integrated into host CD4+ T-cell DNA (primarily resting memory T cells, also tissue macrophages, microglia), estimated 1 million latently infected cells per person on suppressive ART, reservoir half-life 44 months (4+ years) - would take 70+ years to naturally decay even on perfect ART, cells long-lived memory T cells (decades lifespan). Stop ART → viral rebound 50% patients within 2 weeks, 90% within 4 weeks from reservoir reactivation (latent provirus transcribes → virion production → infects new cells → exponential replication). Only 2 HIV cures documented: Timothy Ray Brown ("Berlin Patient" 2008) and Adam Castillejo ("London Patient" 2019) - both underwent myeloablative chemotherapy + allogeneic stem cell transplant from CCR5Δ32/Δ32 homozygous donors for cancer treatment (leukemia), CCR5Δ32 mutation (1% European ancestry) makes cells resistant to R5-tropic HIV (CCR5 co-receptor absent), stem cells reconstituted HIV-resistant immune system, reservoir cleared (combination myeloablation killing infected cells + graft-vs-host eliminating residual reservoir), ART-free >15 years (Brown), >5 years (Castillejo), no viral rebound. Not scalable: Requires matching CCR5Δ32 donor (rare), dangerous procedure (30% mortality risk myeloablation + transplant), only justified for life-threatening cancer not HIV alone. Functional cure goal: Achieve sustained ART-free viral remission without stem cell transplant - virus remains latent but immune control prevents reactivation/replication, quality of life restoration, eliminate daily medication burden/costs/toxicities.
📊 View all HIV therapeutic vaccine trials on ClinicalTrials.gov →
🌍 UNAIDS - Global HIV Statistics →
🌍 NIH/NIAID HIV Cure Research →
🌍 defeatHIV Collaboratory →
📰 Latest HIV Cure News (Google) →